Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

Annals of Hematology

Volumn 90, Issue 8, 2011, Pages 939-946

  Albizua, Enriqueta ^a,b   Gallardo, Miguel ^a   Barrio, Santiago ^a   Rapado, Inmaculada ^a   Jimenez, Ana ^a   Ayala, Rosa ^a   Rueda, Daniel ^a   Sanchez Espiridion, Beatriz ^c   Puigdecanet, Eulalia ^d   Espinet, Blanca ^d   Florensa, Lourdes ^d   Besses, Carles ^d   Martinez Lopez, Joaquin ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

Essential thrombocythemia; Gene expression profile; JAK2; Polycythemia vera; Response to hydroxyurea; RT PCR; Src family kinase (SFK)

Indexed keywords

HYDROXYUREA;

ADULT; AGED; AKT GENE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ERYTHROCYTOSIS; FEMALE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MAPK14 GENE; ONCOGENE SRC; PIK3CA GENE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RNA FINGERPRINTING; SFK GENE; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; POLYCYTHEMIA; POLYCYTHEMIA VERA; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 79960219647     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1179-2     Document Type: Article

References (26)

1. C James V Ugo JP Le Couedic J Staerk F Delhommeau C Lacout, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 7037 1144 1148 15793561 10.1038/nature03546 1:CAS:528:DC%2BD2MXjsF2ltbk%3D (Pubitemid 40663494)
2. A Tefferi J Thiele A Orazi HM Kvasnicka T Barbui CA Hanson, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 8 8
3. G Barosi G Birgegard G Finazzi M Griesshammer C Harrison HC Hasselbalch, et al. 2009 Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference Blood 113 20 4829 4833 19278953 10.1182/blood-2008-09-176818 1:CAS:528:DC%2BD1MXmslalsb8%3D
4. JM Goldman AR Green T Holyoake C Jamieson R Mesa T Mughal, et al. 2009 Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues Leukemia 23 1708 1715 19641523 10.1038/leu.2009.142 1:CAS:528:DC%2BD1MXht1GgtLvJ
5. RL Levine C Belisle M Wadleigh D Zahrieh S Lee P Chagnon, et al. 2006 X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood 107 10 4139 4141 16434490 10.1182/blood-2005-09-3900 1:CAS:528:DC%2BD28XkvFWgs7s%3D Epub 2006 Jan 24 (Pubitemid 43726824)
6. R Kralovics SS Teo S Li A Theocharides AS Buser A Tichelli, et al. 2006 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood 108 4 1377 1380 16675710 10.1182/blood-2005-11-009605 1:CAS:528:DC%2BD28Xot1ymu70%3D (Pubitemid 44232040)
7. JR Lambert T Everington DC Linch RE Gale 2009 In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm Blood 114 14 3018 3023 19541820 10.1182/blood-2009-03-209916 1:CAS:528:DC%2BD1MXht12qurzJ
8. S Li R Kralovics G De Libero A Theocharides H Gisslinger RC Skoda 2008 Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations Blood 111 7 3863 3866 18195094 10.1182/blood-2007-09-111971 1:CAS:528:DC%2BD1cXktlWmt7c%3D
9. F Delhommeau S Dupont V Della Valle C James S Trannoy A Masse, et al. 2009 Mutation in TET2 in myeloid cancers N Engl J Med 360 22 2289 2301 19474426 10.1056/NEJMoa0810069
10. AM Vannucchi P Guglielmelli A Tefferi 2009 Advances in understanding and management of myeloproliferative neoplasms CA Cancer J Clin 59 3 171 191 19369682 10.3322/caac.20009
11. CN Harrison PJ Campbell G Buck K Wheatley CL East D Bareford, et al. 2005 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 1 33 45 16000354 10.1056/NEJMoa043800 1:CAS:528: DC%2BD2MXmtVWjsbs%3D (Pubitemid 41007805)
12. G Barosi C Besses G Birgegard J Briere F Cervantes G Finazzi, et al. 2007 A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group Leukemia 21 2 277 280 17251900 10.1038/sj.leu.2404473 1:CAS:528:DC%2BD2sXotFGrsw%3D%3D (Pubitemid 46158120)
13. L Akerblom A Ehrenberg A Graslund H Lankinen P Reichard L Thelander 1981 Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells Proc Natl Acad Sci USA 78 4 2159 2163 6264464 10.1073/pnas.78.4.2159 1:STN:280:DyaL3M3itlygtQ%3D%3D
14. I Rapado E Albizua R Ayala JA Hernandez L Garcia-Alonso S Grande, et al. 2008 Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases Ann Hematol 87 9 741 749 18575865 10.1007/s00277-008-0512-x 1:CAS:528:DC%2BD1cXptVygtr8%3D
15. I Rapado S Grande E Albizua R Ayala JA Hernandez M Gallardo, et al. 2009 High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms J Mol Diagn 11 2 155 161 19225136 10.2353/jmoldx.2009.080110 1:CAS:528:DC%2BD1MXjs12qs7c%3D
16. A Subramanian P Tamayo VK Mootha S Mukherjee BL Ebert MA Gillette, et al. 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci USA 102 43 15545 15550 16199517 10.1073/pnas.0506580102 1:CAS:528:DC%2BD2MXht1ShtrnO (Pubitemid 41528093)
17. A Pellagatti D Vetrie CF Langford S Gama H Eagleton JS Wainscoat, et al. 2003 Gene expression profiling in polycythemia vera using cDNA microarray technology Cancer Res 63 14 3940 3944 12873988 1:CAS:528:DC%2BD3sXlsFOjtbY%3D (Pubitemid 36917909)
18. R Kralovics SS Teo AS Buser M Brutsche R Tiedt A Tichelli, et al. 2005 Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 Blood 106 10 3374 3376 16081684 10.1182/blood-2005-05-1889 1:CAS:528:DC%2BD2MXht1ehsb7E (Pubitemid 41609168)
19. S Schwemmers B Will CF Waller K Abdulkarim P Johansson B Andreasson, et al. 2007 JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling Exp Hematol 35 11 1695 17764814 10.1016/j.exphem.2007.07.004 1:CAS:528:DC%2BD2sXht1KrtLrE (Pubitemid 47633768)
20. K Shide HK Shimoda T Kumano K Karube T Kameda K Takenaka, et al. 2008 Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F Leukemia 22 1 87 95 18033315 10.1038/sj.leu.2405043 1:CAS:528: DC%2BD1cXmsVyqsg%3D%3D
21. H Chin A Arai H Wakao R Kamiyama N Miyasaka O Miura 1998 Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway Blood 91 10 3734 3745 9573010 1:CAS:528:DyaK1cXjtFersL0%3D (Pubitemid 28225741)
22. VM Zaleskas DS Krause K Lazarides N Patel Y Hu S Li, et al. 2006 Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F PLoS ONE 1 e18 17183644 10.1371/journal.pone.0000018
23. M Wappl E Jaeger B Streubel H Gisslinger I Schwarzinger P Valent, et al. 2008 Dasatinib inhibits progenitor cell proliferation from polycythaemia vera Eur J Clin Investig 38 8 578 584 10.1111/j.1365-2362.2008.01982.x 1:CAS:528:DC%2BD1cXhtVOnu7nJ (Pubitemid 352019138)
24. F Girodon C Schaeffer C Cleyrat M Mounier I Lafont FD Santos, et al. 2008 Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy Haematologica 93 11 1723 1727 18728027 10.3324/haematol.13081
25. O Bock J Neuse K Hussein K Brakensiek G Buesche T Buhr, et al. 2006 Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status Am J Pathol 169 2 471 481 16877349 10.2353/ajpath.2006.060110 1:CAS:528:DC%2BD28XosFalu70%3D (Pubitemid 44156308)
26. WG Stetler-Stevenson N Bersch DW Golde 1992 Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity FEBS Lett 296 2 231 234 1370805 10.1016/0014-5793(92)80386-U 1:CAS:528:DyaK38XhtVWltr8%3D